Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06742957 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis
A Phase 3 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 3
- Development phase
- 560
- Enrollment target
NCT06742957: Completed Phase 3 study, sponsored by Teva Pharmaceuticals USA.
NCT06742957 is a Phase 3 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 560 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06742957, a Phase 3 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 560 participants
- Enrollment target
Study Summary
To compare the safety and efficacy of the test (Tapinarof Cream 1%), placebo (vehicle cream) and reference VTAMA® (Tapinarof Cream 1%) treatments to demonstrate clinical equivalence in patients with plaque psoriasis.
Interventions
- DRUG Placebo
- DRUG Tapinarof Cream 1%
- DRUG VTAMA®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 2024-12-17 |
| Est. Completion | 2025-11-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06742957
The ClinicalTrials.gov registry entry for NCT06742957 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 560 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06742957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06742957 about?
NCT06742957 is a clinical study titled "Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis". To compare the safety and efficacy of the test (Tapinarof Cream 1%), placebo (vehicle cream) and reference VTAMA® (Tapinarof Cream 1%) treatments to demonstrate clinical equivalence in patients with plaque psoriasis.
What is the current status of trial NCT06742957?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 560 participants. The study started on 2024-12-17. Estimated completion is 2025-11-12.
What interventions are being tested in trial NCT06742957?
The interventions under investigation include: Placebo (DRUG), Tapinarof Cream 1% (DRUG), VTAMA® (DRUG).
Who is sponsoring clinical trial NCT06742957?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.